The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

A new, generic, non-steroidal anti-inflammatory drug (NSAID) is now available for managing osteoarthritis (OA) pain in horses ...

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...

Researchers from Cologne, Bochum, Padova and Angers have discovered a novel connection between mitochondrial function, ...

The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...

As detailed in our previous updates, the IRA’s Medicare Drug Price Negotiation Program (the Negotiation Program or Program), ...

A European research collaboration has found that besides regulating the fusion of mitochondria, Mitofusin 2 also ensures protein quality control. This discovery could open up new routes to treating ...

Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase 3 study.

Among the total systemic sclerosis cohort, 14% of individuals were categorized as frail and 53% as prefrail, with frailty status linked to an increased risk for mortality.